Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
NEW YORK--(BUSINESS WIRE)--Oct 30, 2023--
Source: eagletribune.com
Stay updated with breaking news from Pat Lorusso. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK--(BUSINESS WIRE)--Oct 30, 2023--